title: Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity.
abstract: OBJECTIVE
  To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP).
  
  
  METHODS
  Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations.
  
  
  RESULTS
  Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively).
  
  
  CONCLUSIONS
  The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies.
authors.affiliation: Department of Ophthalmology, ROP Training and Treatment Center, Zeynep Kamil Maternity and Children's Disease Training and Research Hospital, Istanbul, TR.
authors.forename: Murat
authors.initials: M
authors.lastname: Gunay
authors.affiliation: Department of Ophthalmology, ROP Training and Treatment Center, Zeynep Kamil Maternity and Children's Disease Training and Research Hospital, Istanbul, TR.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Celik
authors.affiliation: Department of Ophthalmology, Umraniye Training and Research Hospital, Istanbul, TR.
authors.forename: Betul Onal
authors.initials: BO
authors.lastname: Gunay
authors.affiliation: Department of Pediatrics, Zeynep Kamil Maternity and Children's Disease Training and Research Hospital, Istanbul, TR.
authors.forename: Alev
authors.initials: A
authors.lastname: Aktas
authors.affiliation: Department of Neonatology, Zeynep Kamil Maternity and Children's Disease Training and Research Hospital, Istanbul, TR.
authors.forename: Guner
authors.initials: G
authors.lastname: Karatekin
authors.affiliation: Department of Neonatology, Zeynep Kamil Maternity and Children's Disease Training and Research Hospital, Istanbul, TR.
authors.forename: Fahri
authors.initials: F
authors.lastname: Ovali
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001724:Birth Weight; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D058449:Intravitreal Injections / Q000379:methods*; D017075:Laser Coagulation / Q000379:methods; D016015:Logistic Models; D008297:Male; D012030:Refractive Errors / Q000209:etiology; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab